DrugBank

JULY 24, 2024

This drug, which targets a specific protein-protein interaction (PPI), took over two decades of research and development but has proven highly effective in treating certain cancers. By blocking this interaction, researchers aim to unleash p53's full tumor-suppressing potential.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

Broad Institute

AUGUST 24, 2022

Credit: NCI ) Researchers at Baylor College of Medicine, the Broad Institute of MIT and Harvard, and Washington University in St. The team then conducted analyses that triangulated treatment response, chromosomal deletion or gain, and concordant decreases or increases in mRNA and protein expression.

DNA 52

DNA Protein Expression Treatment Protein Production 52

The Pharma Data

MARCH 30, 2021

Fibroblast activation protein (FAP) is a cell-surface protein expressed at low levels in most normal adult tissues, but over-expressed in common cancers, particularly on cancer-associated fibroblasts that form the tumor stroma, which is essential for growth 1 ,2 ,3 ,4.

Licensing 52

Licensing Licensing Therapies Protein Expression 52

Drug Discovery World

MAY 2, 2023

Steve Wowk , VP, Business Unit and General Management of Integrated DNA Technologies, shared with DDW the value of CRISPR-Cas9 in drug discovery. Some of the most important breakthroughs in pharmaceutical research were adapted from naturally occurring phenomena. The gRNA is accompanied by the Cas9 enzyme responsible for cutting DNA.

DNA 130

DNA RNA Protein Expression Drugs 130

Broad Institute

JUNE 27, 2024

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. Previous research has shown that as little as 21 percent elimination of the protein can improve symptoms. Credit: Neumann EN, Bertozzi TM, et al.

Disease 142

Disease Therapies Engineering Clinical Trials 142

Drug Discovery World

APRIL 30, 2024

Whilst research into mRNA has been ongoing for decade, interest has sparked in recent years and research has begun to expand into areas of vaccinology, infectious diseases and other indications. mRNA-based approaches can produce proteins / peptides by using protein synthesis which is processed in a transfected cell 1.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Codon

DECEMBER 10, 2023

As money poured into wartime research programs, physics shifted from a field of brilliant individuals to one of well-managed teams. Biology has had a few large-scale research programs, such as the Human Genome Project , but nowhere near the same number as physics. For one, biology research is inherently broad.

Protein Expression 95

Protein Expression DNA Laboratories Engineering 95

Codon

DECEMBER 10, 2023

As money poured into wartime research programs, physics shifted from a field of brilliant individuals to one of well-managed teams. Biology has had a few large-scale research programs, such as the Human Genome Project , but nowhere near the same number as physics. For one, biology research is inherently broad.

Protein Expression 71

Protein Expression DNA Laboratories Engineering 71

Drug Discovery World

FEBRUARY 28, 2023

The half-life of proteins expressed through the mRNA technology is also much longer than those of direct protein delivery, which suggests that it could be more effective as a treatment strategy for rare diseases. She is passionate about advancing research in the pursuit of healthier lives for all.

Disease 130

Disease Treatment Vaccine DNA 130

Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It To demonstrate the utility of the company’s SYNTAX system in gene assembly, the 1.7 kb Influenza A hemagglutinin gene was used as a model system.

Protein Expression 147

Protein Expression Engineering DNA Therapies 147

Drug Discovery World

NOVEMBER 9, 2023

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.

Engineering 130

Engineering Therapies Protein Production Science 130

Conversations in Drug Development Trends

AUGUST 14, 2024

Recent Advancements in Biomarker Research The latest advancements in biomarker research have further elevated the biomarker’s role in disease diagnosis, treatment, and monitoring. The analysis of circulating tumor DNA (ctDNA) in a liquid biopsy can also permit genotyping and help monitor the effectiveness of chemotherapy.

Treatment 78

Treatment Protein Expression Therapies Disease 78

Drug Target Review

SEPTEMBER 10, 2024

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. For example, advances in media and feeds have contributed to higher cell protein expression by optimising nutrient availability and reducing accumulation of waste products within a culture.

Clinical Supply 64

Clinical Supply Drug Development Production Animal Testing 64

Drug Discovery World

NOVEMBER 13, 2023

Thereafter, the following presentations will take place: Melody Shahsavarian, PhD, Digital Biologics Platform, Large Molecules Research, Sanofi, on: ‘Enhancing antibody discovery with generative AI’. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Engineering 147

Engineering Science Bioinformatics Vaccine 147

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

MARCH 20, 2023

In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Zolgensma is now approved in more than 47 countries and more than 3,000 patients have been treated with Zolgensma globally across clinical trials, managed access programs, and in the commercial setting.

Licensing 40

Licensing Licensing Clinical Trials Therapies 40

Codon

APRIL 9, 2023

This is Codon Digest, my weekly roundup of research, news, and industry highlights about the future of biology. ” This technology could be used to design protein therapeutics that can bind to, and “shut down,” harmful or misfolded proteins in living cells. Nucleic Acids Research. Nucleic Acids Research.

Therapies 52

Therapies RNA Engineering Vaccine 52

Drug Target Review

MAY 4, 2023

A new approach developed by researchers at New York University (NYU) and the New York Genome Centre, US, combines genetic association studies, gene editing, and single-cell sequencing to address human genetic challenges and discover causal variants and genetic mechanisms for blood cell traits.

Disease 52

Disease Small Molecule Protein Expression Research 52